
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma is a promising company with potential for growth in the oncology sector through their novel CAR T-cell therapies for LBCL and solid tumors. The company may face some setbacks due to delays in manufacturing, but its strong leadership and focus on commercialization make it a strong competitor in the CAR T market. With the growing demand for CAR T therapies, Lyell Immunopharma has the potential to secure additional funding and become a leader in the field. Their patented technology and clinical development progress put them in a strong position for success.
Bears say
Lyell Immunopharma is executing a bold strategy to commercialize its CAR-T candidate, ronde-cel, in DLBCL and LYL273 in 3rd line mCRC. However, there are potential safety concerns and regulatory headwinds that may delay expected filing dates, resulting in a lower probability of success for these programs. Additionally, the potential market size for both products is relatively small compared to other commercially successful CAR-T therapies.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares